NanoSyrinx appoints Jane Dancer to the Board as a new NED

NanoSyrinx is delighted to announce that Jane Dancer has agreed to join the Board and is bringing with her a wealth of business development and strategic knowledge for driving value from platform companies.

Jane is a well-known figure in the sector, having served as CBO at F-Star, Cambridge Antibody Technologies, as well as VP for Cellzome, and much more besides!

Jane will be instrumental in supporting the team as we build partnerships over the course of the next couple of years and the team is excited to be working together.

Full press release details can be found here:

Follow us on social media to stay up to date!


Read more news

Anthony Johnson, NanoSyrinx NED

NanoSyrinx appoints Anthony Johnson as Non-Executive Director

Coventry, UK, 10 November 2023: NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director. Tony’s appointment forms part of the Company’s ongoing strategy to expand and strengthen its leadership team as the Company prepares for […]

Read more

NanoSyrinx to feature in PwC’s Life Sciences Future50 Report

We are delighted to be showcased as one of the 50 companies in PwC UK’s  ‘Life Sciences Future 50’ report, illustrating the world-class science and innovation being led by the UK’s life sciences sector to solve some of the most important challenges in scientific research and human healthcare. Find out more here:

Read more

NanoSyrinx in Parliament

Our Founder and CEO, Joe Healey, was invited by the Parliamentary and Scientific Committee (P&SC – to discuss the future and potential of Synthetic Biology for the UK and for human health. The UK has a stated (and laudable) ambition to become a “Scientific Superpower”, and Synthetic Biology is intimately tied to that vision. […]

Read more